Advisory Committee on Compensation, Nominations and Other Matters with Outside Director Participation
First written in FY2017. 1 of 3 entries say "Advanced", first in FY2020. Latest entry: FY2026.
Rohto Pharmaceutical moved to the "Worse" side of this theme in 2026, 4 years after the typical company in this theme (2022).
7 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「At a meeting of the board of directors held on 13 May 2026, the company resolved that the nomination committee and compensation committee would be abolished as of 24 June 2026 and that a new nomination and compensation committee would be established.」
The policy has changed from a structure with separate Nominating and Compensation Committees to their integration into a Nominating and Compensation Committee effective 24 June 2026. - FY2020AdvancedAnnual report
「The Nominating Committee comprises 3 directors, at least half of whom are outside directors.」
The company has moved from the previous description of an Advisory Committee on Compensation, Nominations and Other Matters to a structure with separate Nominating and Compensation Committees, each comprising 3 members, at least half of whom are outside directors. - FY2017First statedAnnual report
「The voluntary Advisory Committee on Compensation, Nominations and Other Matters, which comprises at least half outside directors, considers compensation structures and levels and makes recommendations to the Board of Directors before decisions are made.」
The company describes a system for considering the structure and levels of director compensation through a voluntary Advisory Committee on Compensation, Nominations and Other Matters, in which outside directors comprise at least half the members.